Ana is a molecular biologist enthusiastic about innovation and communication. In her role as a science writer she wishes to bring the advances in medical science and technology closer to the public, particularly to those most in need of them. Ana holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, during which she focused her research on molecular biology, epigenetics and infectious diseases.
Having ankylosing spondylitis more than doubles the risk of developing depression, and the presence of additional chronic conditions exacerbates this risk, a South Korean population-based study reports. Older female ... Read more
Reducing the dose of TNF blockers by about half is nearly as effective as the standard dose taken by ankylosing spondylitis patients who are in stable remission, a clinical trial shows. Reducing ... Read more
Anti-TNF alpha therapy is able to significantly restore ankylosing spondylitis patients’ capacity to exercise after a treatment period of four months, a small study suggests. After treatment, patients in the ... Read more
Filgotinib, an investigational therapy for ankylosing spondylitis, was able to significantly reduce disease activity, according to recent Phase 2 study results announced by Gilead Sciences and Galapagos biotech companies. The TORTUGA trial reached ... Read more
Higher levels of fatigue are related to the degree of disability at work among ankylosing spondylitis (AS) patients treated with the biologic therapy Enbrel (etanercept), an observational study shows. The ... Read more
Therapy with anti-tumor necrosis factor (anti-TNF) is highly effective in people with ankylosing spondylitis. But researchers suggest that patients whose treatment lost its effectiveness or resulted in adverse events ... Read more
Pin It on Pinterest